preeclampsia
(4)
Lōvu Health
Lōvu Health is a Cupertino-based digital maternal health company that follows mother and baby from pre-conception through two years postpartum. It pairs connected home devices - a blood pressure monitor, smart scale and fetal Doppler - with a pregnancy navigator, an OB-facing dashboard, and a marketplace of 50+ specialty vendors, using real-time remote patient monitoring and AI to catch complications like preeclampsia and perinatal depression earlier.
Avilar Therapeutics
Avilar Therapeutics is a Waltham, Massachusetts biopharmaceutical company pioneering the degradation of extracellular and membrane-bound proteins. Its ATAC (ASGPR Targeting Chimera) platform uses bifunctional small molecules that grab a disease-causing protein floating in circulation and shuttle it into the liver's endolysosome to be destroyed, extending the reach of targeted protein degradation beyond the inside of the cell. Launched in 2021 with backing from RA Capital, Avilar is applying the platform to autoimmune disease, preeclampsia, and other conditions driven by proteins that conventional drugs struggle to address.
Mirvie
Mirvie is a South San Francisco biotech using cell-free RNA signatures and machine learning to predict pregnancy complications - preeclampsia, preterm birth, fetal growth restriction - months before symptoms appear. Its flagship product Encompass is a blood test built on a foundational study of nearly 11,000 pregnancies.
Maneesh Jain
Maneesh Jain is the CEO and Co-founder of Mirvie, a South San Francisco-based biotech company pioneering RNA-based blood tests to predict pregnancy complications like preeclampsia and preterm birth months before symptoms occur. A serial entrepreneur with 20+ years in life sciences and more than $1.5B in combined exits across five prior startups - including Ion Torrent (acquired by Life Technologies) and Cirina (acquired by GRAIL) - Jain trained at the Stanford Genome Technology Center and holds a BS from Caltech and a Master's in Applied Physics from Stanford. Mirvie has raised over $90 million from investors including Khosla Ventures, GV, General Catalyst, and the Gates Foundation, and received FDA Breakthrough Device Designation for its preeclampsia risk test in 2022.